RTP Mobile Logo
Select Publications

Champiat S et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016;27(4):559-74. Abstract

Collins L et al. Skin cancer and immunosuppression. Dermatol Clin 2019;37(1):83-94. Abstract

Falchook GS et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer 2016;4:70. Abstract

Grob JJ et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase II trial (KEYNOTE-629).  J Clin Oncol 2020;JCO1903054. Abstract

Jarkowski A 3rd et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): The Roswell Park experience and a review of the literature. Am J Clin Oncol 2016;39(6):545-8. Abstract

Lam JKS et al. Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion. Head Neck 2018;40(5):985-92. Abstract

Maubec E et al. Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase 2 results from CARSKIN. ASCO 2019;Abstract 9547.

Migden MR et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020;21(2):294-305. Abstract

Migden MR et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379(4):341-51. Abstract

Nehal KS, Bichakjian CK. Update on keratinocyte carcinomas. N Engl J Med 2018;379(4):363-74. Abstract

Porceddu SV et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: The randomized phase III TROG 05.01 trial. J Clin Oncol 2018;36(13):1275-83. Abstract

Rischin D al. Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. ASCO 2020;Abstract 10018.

Rogers H et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol 2015;151(10):1081-6. Abstract

Rothermel LD et al. Current immunotherapy practices in melanoma. Surg Oncol Clin N Am 2019;28(3):403-18. Abstract

Ruiz ES et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th edition vs the Brigham and Women’s Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol 2019;155(7):819-25. Abstract

Topalian SL et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016;16(5):275-87. Abstract

Venables ZC et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the UK 2013-15: A cohort study. Br J Dermatol 2019;181(3):474-82. Abstract

Yarchoan M et al. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017;377:2500-1. Abstract